RNS Number : 3364U
Polarean Imaging PLC
24 January 2025
 

Polarean Imaging Plc

("Polarean" or the "Company")

                                                                                                                                                  

Block Listing Six Monthly Return

 

Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

 

Name of applicant:

Polarean Imaging Plc

Name of scheme:

Polarean Share Option Plan

Number and class of securities originally admitted:

8,000,000 ordinary shares of £0.00037 each

Date of admission:

29 July 2021

Period of return:

From:

27 July 2024

To:

24 January 2025

Balance of unallotted securities under scheme(s) from previous return:

808,917

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

 

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

 

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

808,917

Total number of securities in issue at the end of the period

1,207,032,781






 

Name of contact:

Charles F. Osborne, Jr., Chief Financial Officer

Telephone number of contact:

+ 44 (0)20 7933 8780 or polarean@walbrookpr.com

 

Enquiries:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Christopher von Jako, Chief Executive Officer

Via Walbrook PR

Charles Osborne, Chief Financial Officer

 


 

Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)

+44 (0)20 7710 7600

Nicholas Moore / Nick Harland / Ben Good



Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Anna Dunphy /Phillip Marriage

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com)

 

Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPKBBQQBKDCDB
Polarean Imaging (LSE:POLX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025 Plus de graphiques de la Bourse Polarean Imaging
Polarean Imaging (LSE:POLX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025 Plus de graphiques de la Bourse Polarean Imaging